M
Michelle DeSilvio
Researcher at Novartis
Publications - 5
Citations - 789
Michelle DeSilvio is an academic researcher from Novartis. The author has contributed to research in topics: Prostate cancer & Carboplatin. The author has an hindex of 4, co-authored 5 publications receiving 112 citations.
Papers
More filters
Journal ArticleDOI
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
Oliver Sartor,Johann S. de Bono,Kim N. Chi,Karim Fizazi,Ken Herrmann,Kambiz Rahbar,Scott T. Tagawa,Luke T. Nordquist,Nitin Vaishampayan,Ghassan El-Haddad,Chandler H Park,Tomasz M. Beer,Alison Armour,Wendy J Pérez-Contreras,Michelle DeSilvio,Euloge Kpamegan,Germo Gericke,Richard A. Messmann,Michael J. Morris,Bernd J. Krause,Vision Investigators +20 more
TL;DR: In this paper, Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic castration-resistant prostate cancer and remains fatal despite recent advances in medical technology.
Journal ArticleDOI
Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION).
Michael J. Morris,Johann S. de Bono,Kim N. Chi,Karim Fizazi,Ken Herrmann,Kambiz Rahbar,Scott T. Tagawa,Luke T. Nordquist,Nitin Vaishampayan,Ghassan El-Haddad,Chandler H. Park,Tomasz M. Beer,Wendy J Pérez-Contreras,Michelle DeSilvio,Euloge Kpamegan,Germo Gericke,Richard A. Messmann,Bernd J. Krause,A. Oliver Sartor +18 more
TL;DR: This data indicates that prostate-specific membrane antigen (PSMA) is highly expressed in patients with metastatic castration-resistant prostate cancer and this data points to a need for further studies to establish a causative agent for this disease.
Journal ArticleDOI
Phase IB dose escalation and expansion study of AKT inhibitor afuresertib with carboplatin and paclitaxel in recurrent platinum-resistant ovarian cancer
Sarah P. Blagden,Sarah P. Blagden,Anne Hamilton,Anne Hamilton,Linda Mileshkin,Shirley Wong,Agnieszka Michael,Marcia Hall,Jeffrey C. Goh,Jeffrey C. Goh,Alla Lisyanskaya,Michelle DeSilvio,Eleni Frangou,Euan A. Stronach,Prashanth Gopalakrishna,Tarek Meniawy,Tarek Meniawy,Hani Gabra,Hani Gabra +18 more
TL;DR: Afuresertib plus PC demonstrated efficacy in recurrent PROC with the MTD of afURESertib defined as 125 mg/day, as well as safety and tolerability, as per RECIST version 1.1.
Journal ArticleDOI
Final overall survival analysis of a phase II trial evaluating vinorelbine and lapatinib in women with ErbB2 overexpressing metastatic breast cancer.
Wolfgang Janni,Tomasz Sarosiek,Boguslawa Karaszewska,Joanna Pikiel,Elżbieta Starosławska,Piotr Potemski,Christoph Salat,Etienne Brain,Christian Caglevic,Kathryn Briggs,Kim Mahood,Michelle DeSilvio,Luca Marini,Christos Papadimitriou +13 more
TL;DR: Assessment of the final OS in this study at 40 months post-randomisation suggested that lap+vin offers an effective treatment option for women with HER2-positive MBC.
Journal ArticleDOI
Phase I/II dose-escalation and expansion study of afuresertib + carboplatin and paclitaxel in recurrent ovarian cancer.
Sarah P. Blagden,Hani Gabra,Anne Hamilton,Shirley Wong,Agnieszka Michael,Linda Mileshkin,Marcia Hall,Jeffrey C. Goh,Alla Lisyanskaya,Michelle DeSilvio,Dany Habr,Shelby Gainer,Prashanth Gopalakrishna,Tarek Meniawy +13 more
TL;DR: Whether the oral pan-AKT inhibitor afuresertib can restore sensitivity to platinum Rx and reverse acquired resistance to standard Rx in recurrent OC is investigated.